Zhang, X., Goel, V., & Robbie, G. J. (2019). Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis. J Clin Pharmacol.
Dyfyniad Arddull ChicagoZhang, Xiaoping, Varun Goel, and Gabriel J. Robbie. "Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis." J Clin Pharmacol 2019.
Dyfyniad MLAZhang, Xiaoping, Varun Goel, and Gabriel J. Robbie. "Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis." J Clin Pharmacol 2019.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.